Company Overview and News

FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

2018-02-21 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that the FDA has accepted its new drug application (NDA) for late stage pipeline candidate, Inbrija. The FDA is expected to give its decision on the candidate on Oct 5, 2018. The company had resubmitted the NDA for Inbrija in December 2017.
Upvote Downvote

Parkinson's Disease Space Again Under Spotlight This Week

2018-01-11 zacks
The spotlight is again on the Parkinson’s Disease (PD) space this week. It has turned out to be an important focus area with Adamas Pharmaceuticals (ADMS - Free Report) launching its PD drug, Gocovri, and Pfizer (PFE - Free Report) dropping its plans to develop treatments for the indication.
Upvote Downvote

Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

2017-12-08 zacks
Acorda Therapeutics (ACOR - Free Report) announced that it has resubmitted the new drug application (NDA) for its late stage pipeline candidate, Inbrija, to the FDA.  Following the news, shares of the company gained by about 1.9%. So far this year, shares of the company have increased 10.4% compared with the industry’s gain of 0.7%.
Upvote Downvote

Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

2017-11-22 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) recently announced that it is scrapping development of one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. The decision was taken after some serious safety issues were observed in the phase III study, which was reported last week.
Upvote Downvote

Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

2017-11-21 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease (“PD”) candidates, tozadenant.
Upvote Downvote

Understanding Aducanumab's Potential In Alzheimer's

2017-11-21 seekingalpha
Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing.
Upvote Downvote

Acorda Reports Death in Parkinson's Trials, Stock Down 40%

2017-11-16 zacks
Acorda Therapeutics, Inc.'s (ACOR - Free Report) shares sank 40% on Wednesday after the company announced death of several patients in a late-stage study, evaluating one of its lead Parkinson’s disease (“PD”) candidates, tozadenant.
Upvote Downvote

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

2017-09-26 247wallst
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer’s disease. This disease has ravaged an aging American population. More than 5 million Americans were already living with Alzheimer’s in 2014, and that number is expected to triple as the population continues to age.
Upvote Downvote

Global Electric Vehicles Forecasts, Analysis and Opportunities Report 2017-2037

2017-08-15 prnewswire
The "Electric Vehicles 2017-2037: Forecasts, Analysis and Opportunities" report has been added to Research and Markets' offering.
Upvote Downvote

Global Huntington's Disease Therapeutics Market Growth at CAGR of 14.75%, 2017-2021 - Key Vendors are F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology & Teva Pharmaceutical

2017-08-15 prnewswire
The "Global Huntington's Disease Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.
Upvote Downvote

Prana Biotechnology joins with Takeda to investigate lead drug

Prana Biotechnology Limited (ASX:PBT, NASDAQ:PRAN) has executed a research collaboration with Takeda Pharmaceuticals International to study Prana’s lead movement disorders compound.
Upvote Downvote

Prana Biotechnology shares surge after journal publication

Shares in Prana Biotechnology (NADSAQ:PRAN) surged 19% and was earlier higher in New York as it said an article about early data on PBT434 had been accepted in a peer review journal.
Upvote Downvote

Prana Bio shows some life; shares up 44%

2017-01-06 seekingalpha
Thinly traded Prana Biotechnology (PRAN +44%) continues its up move on an impressive 29x surge in volume. Shares have rallied almost 70% since trading resumed Tuesday.
Upvote Downvote

Prana Biotech not quite there for start of European late-stage study of lead product candidate in Huntington's

2016-12-23 seekingalpha
With the aim of getting sign-off from regulators to initiate a Phase 3 clinical trial assessing lead product candidate PBT2 in Huntington's disease (HD), Prana Biotechnology (NASDAQ:PRAN) recently concluded meetings with the Medical and Healthcare Regulatory Agency in London and Medical Products Agency in Stockholm. Both recommended additional preclinical testing to establish the reversibility of the neurotoxicity observed in a dog study before considering a late-stage study in humans.
Upvote Downvote

New Data From Trial Presented At American Neurological Association Annual Meeting

2016-10-18 devicespace
MELBOURNE, Australia--(BUSINESS WIRE)--Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

23h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...